biote (NASDAQ:BTMD) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

biote (NASDAQ:BTMD) posted its earnings results on Wednesday. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01, Zacks reports. biote had a negative return on equity of 32.41% and a net margin of 5.20%.

biote Stock Performance

NASDAQ BTMD traded down $0.03 on Wednesday, hitting $4.10. 286,012 shares of the stock were exchanged, compared to its average volume of 138,624. biote has a 52-week low of $4.03 and a 52-week high of $8.44. The firm has a market capitalization of $222.78 million, a P/E ratio of 15.77 and a beta of 1.07. The stock has a fifty day moving average price of $5.11 and a two-hundred day moving average price of $5.60.

Wall Street Analyst Weigh In

Separately, Craig Hallum started coverage on shares of biote in a research report on Monday, December 16th. They set a “buy” rating and a $12.00 price objective for the company.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.